The company is conducting a search for a new CFO. Until a replacement is named, Dreyer’s daily finance responsibilities will be handled by its long-tenured finance leadership; President and CEO Harold C. Flynn Jr. will handle investor relations and other administrative duties.
“We thank David for his service during this very important time of the transformation of BIOLASE,” said Flynn. “We have made substantial progress in building BIOLASE into a more disciplined and efficient commercial enterprise, and we thank David for his positive contributions to these efforts. Our financial organization has strengthened during David’s tenure, and we wish him the very best in his future endeavors.”
BIOLASE Inc. develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment, including digital X-rays and CAD/CAM scanners. BIOLASE’s products are focused on technologies that advance the practice of dentistry to both dentists and their patients. BIOLASE’s proprietary laser products incorporate approximately 255 patented and 90 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its products provide technology that delivers the best results for dentists and patients. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold approximately 32,800 laser systems to date in more than 90 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer markets. The company is based in Irvine, Calif.